Vaccines market to be worth $57.5 billion by 2025, report says

26 July 2019

The global vaccines market will increase at a compound annual growth rate (CAGR) of 7% from 2018 to reach $57.5 billion by 2025, according to a new report.

This growth will be driven by the high prevalence of diseases, increasing government initiatives towards immunization, rising adoption rates, technological advances in the vaccine industry and a strong pipeline, says the Meticulous Research report.

North America commands the largest share of the vaccines market thanks to its well-established vaccination programs, increasing prevalence of diseases, growing adoption of advanced vaccines, and a large pool of key players.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK